Customer Support

High-quality Products. High-quality Customer Service.

Lundbeck is dedicated to providing high-quality products and customer service to patients and the healthcare professionals who care for them. The following is important contact information for our marketed products.

If this is a medical emergency, please call 911 or visit your nearest emergency room center.

For information about Abilify Maintena® (aripiprazole) for extended-release injectable suspension:
Medical Information Inquiries for Healthcare Professionals: 800-441-6763
For All Inquiries: 800-438-9927
Website: www.abilifymaintena.com
For Abilify Maintena full Prescribing Information including Boxed Warning, and Medication Guide, click here

Abilify Maintena is a registered trademark of Otsuka Pharmaceutical Co. Ltd. (Japan)

For information about Carnexiv (carbamazepine) injection:
Medical Information Inquiries for Healthcare Professionals: 866-402-8520
Website: www.Carnexiv-US.com  
For Carnexiv full Prescribing Information including Boxed Warning, click here

For information about NORTHERA® (droxidopa):

Medical Information Inquiries for Healthcare Professionals: 866-402-8520
All Other Inquiries: 844-601-0101
Website: www.NORTHERA.com  
For NORTHERA full Prescribing Information including Boxed Warning, click here

For information about ONFI® (clobazam) CIV:
Medical Information Inquiries for Healthcare Professionals: 866-402-8520

All Other Inquiries: 855-345-6634
Website: www.ONFI.com
For ONFI full Prescribing Information including Boxed Warning, click here, Medication Guide, click here, and Instructions for Use, click here

For information about REXULTI® (brexpiprazole):
Medical Information Inquiries for Healthcare Professionals: 800-441-6763
For All Inquiries: 800-438-9927  
Website: www.Rexulti.com
For Rexulti full Prescribing Information including Boxed Warning, and Medication Guide, click here

Rexulti is a registered trademark of Otsuka Pharmaceutical Co. Ltd. (Japan)

For information about Sabril® (vigabatrin) tablets, for oral use and Sabril (vigabatrin) powder for oral solution:
Medical Information Inquiries for Healthcare Professionals: 866-402-8520

All Other Inquiries: 888-457-4273

Website: http://sabril.net/
For Sabril Medication Guide, click here, full Prescribing Information including Boxed Warning, click here, and Instructions for Use, click here

For information about Trintellix (vortioxetine) Tablets (Trintellix previously known as Brintellix):
For All Inquiries: 877-825-3327
Website: www.trintellix.com
For Trintellix full Prescribing Information including Boxed Warning, click here, and Medication Guide, click here

Trintellix is a trademark of H. Lundbeck A/S and used under license by Takeda Pharmaceuticals America, Inc. 

For information about Xenazine® (tetrabenazine) Tablets:
Medical Information Inquiries for Healthcare Professionals: 866-402-8520

All Other Inquiries: 888-882-6013

Website: http://www.xenazineusa.com
For full Prescribing Information including Boxed Warning, click here, and Medication Guide, click here

Xenazine is a registered trademark of Valeant International Bermuda

Important Contact Information for U.S. Residents

Dial 911 if you are experiencing a medical emergency. Please visit Customer Support for important contact information relating to our products, including:
 

- Medical information
- Drug safety information
- Product ordering information


You are encouraged to report negative side effects to the FDA.
Visit www.fda.gov/medwatch, or call
1-800-FDA-1088.

 

As of January 18, 2013, the following products were sold to Recordati Rare Diseases: Chemet (succimer), Cosmegen (dactinomycin for injection), Desoxyn (methamphetamine hydrochloride tablets, USP), Elspar (asparaginase), Indocin (indomethacin for injection), Mustargen (mechlorethamine HCl for injection), NeoProfen (ibuprofen lysine), Panhematin (hemin for injection), Peganone (ethotoin tablets, USP) and Tranxene (clorazepate dipotassium). For information about these products, please contact Recordati at 888.575.8344 or visit http://www.recordatirarediseases.com/.

For Canadian Residents

For Canadian residents seeking information about Frisium® (clobazam) or Sabril® (vigabatrin), click here

Expanded Access Policy

On a case-by-case basis, Lundbeck (the "Company) considers requests from US-licensed treating physicians for access to investigational products in Phase II or Phase III of development for patient treatment purposes. Treating physicians may request more information by contacting the Company at (866) 402-8520. Receipt of a request for information will be acknowledged within 10 business days. 

 

The factors that the Company will consider upon receiving a request include:

  • - the clinical situation and need of the patient for whom the physician seeks access, including whether the patient has a serious or life-threatening illness for which there is no viable alternative therapy;
  • - whether the treating physician believes that the potential benefits of the experimental product will outweigh any potential risks to her or her patient;
  • - the ability of the treating physician to ensure compliance with applicable investigational new drug regulatory requirements, and good clinical practices;
  • - the extent to which currently available data are sufficient to make an assessment of the benefit and risk of the proposed use of the investigational product and for the patient to provide informed consent for such use;
  • - whether regulatory authorities and institutional review boards/ethics committees have approved, or are likely to approve, expanded access to the investigational medicine;
  • - whether the medicine is under active development (i.e., the product is already approved, or the development program been discontinued);
  • - whether the patient either is ineligible for or is unable to participate in a clinical trial for the investigational product;  
  • - the impact of providing access to an investigational product on the development program for that product, including the ability to complete patient enrollment and other aspects of the clinical trials necessary to secure product approval, and the available supply of the investigational medicine; and
  • - such other factors as the Company may deem appropriate to consider, in its full discretion.

 

This policy is not a guarantee of access to any Company investigational drug. The Company reserves the right to revise or revoke this policy at any time. 

 

Information about our ongoing expanded access trials may be found by searching for "Lundbeck" at www.clinicaltrials.gov.

 

You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck.